Dr.Evidence™ Expands Capabilities of AI-powered Medical Search Engine

DocSearch extends platform functionality and adds new data sources

SANTA MONICA, Calif.--(BUSINESS WIRE)--Dr.Evidence™, the leading medical intelligence platform for life sciences companies, today announced groundbreaking enhancements to their market-leading medical search solution, DocSearch. DocSearch has expanded its coverage to include global patents and grants to its database and included the ability to identify new connections and generate hypotheses based on published literature with a Drugs-Targets module.

DocSearch is a specialized, real-time medical search engine powered by AI that generates actionable insights based on the universe of published medical information, real-world evidence and proprietary data. With the addition of the new Drugs-Targets module, it becomes possible to get more from published literature by establishing links between chemicals, targets, and disease, helping identify previously unrealized connections. This literature-based discovery approach creates the opportunity for researchers to explore a wide range of new hypotheses.

“This expanded functionality drives potential breakthroughs by connecting existing knowledge in literature in new ways,” said Dr.Evidence’s Head of Search, Arturo Devesa. “Using the principle of Swanson Linking, we can uncover previously hidden connections between supposedly unrelated concepts in the biomedical literature and see possibilities emerging, leading to new hypotheses, in-silico drug-target profiling, target identification search, and disease-drug-target links and associations discovery search.”

In addition to the Drugs-Targets module, DocSearch has added global patents (25 million) and grants (600,000) to its database. The addition of these new data sources will support more robust, comprehensive searches and will be instrumental in an upcoming DocSearch feature, Literature Lifecycle Visualization. The visualization will enable users to track a drug or treatment’s end-to-end literature life cycle from grant to clinical trial to PubMed publication to patent to FDA label to congresses to news and social media.

Dr.Evidence’s Chief Executive Officer, Bob Battista, commented, “The significant expansion of DocSearch capabilities and data sources is in direct response to the needs of our life sciences clients. We are committed to rapidly advancing the Dr.Evidence platform to positively impact patients’ lives by uncovering insights that drive innovation.”

About Dr.Evidence™

Dr.Evidence™ is the leading medical intelligence platform for life sciences companies that enables teams to identify breakthrough insights grounded in the vast universe of published medical information, real-world evidence and proprietary data. It pushes the boundaries of healthcare technology and allows for new possibilities in science, enabling more informed decision making and faster time-to-market for accelerated impact.